Experts dont know what percentage of people taking the new class of weight loss drugs are at risk of eating disorders, because there are no published clinical trials addressing the question, said Keshen, who would like to see a rigorous study
BMJ Open 2019;9(12):e030234
Follow your healthcare providers dosage instructions for optimal results
Right now, its unclear how Ozempic may increase the risk of vision loss caused by NAION
Waist at the navel, hips at the widest point, chest at nipple level, and one thigh at the midpoint between knee and hip
September 1, 2025: FDA Approves Wegovy for Fatty Liver Disease The FDA has granted a new indication for Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease in adults with moderate to advanced fibrosis